A Randomized, Open-label, Crossover Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets Produced by Two Different Processes in Healthy Chinese Male Volunteers
Latest Information Update: 17 May 2019
Price :
$35 *
At a glance
- Drugs Savolitinib (Primary)
- Indications CNS cancer; Gastric cancer; Lung cancer; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma
- Focus Pharmacokinetics
- Sponsors Hutchison MediPharma
- 15 May 2019 Status changed from not yet recruiting to completed.
- 07 Mar 2019 New trial record